EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Nassar, Amin
Adib, Elio
Feng, Jamie
Aredo, Jacqueline V.
Parikh, Kaushal
Harris, Jeremy Phillip
Manana, Ana I. Velazquez
Ragavan, Meera Vimala
Lin, Jessica Jiyeong
Piotrowska, Zofia
Fitzgerald, Bailey Gleason
Grohe, Christian
Sankar, Kamya
Neal, Joel W.
Wakelee, Heather A.
Shepherd, Frances A.
Herbst, Roy S.
Naqash, Abdul Rafeh
Goldberg, Sarah B.
Kim, So Yeon
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Stanford Canc Inst, Stanford, CA USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Calif Irvine, Orange, CA USA
[7] Univ Calif San Francisco, San Francisco, CA USA
[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Icahn Sch Med Mt Sinai, New York, NY USA
[11] ELK Berlin, Dept Resp Dis, Berlin, Germany
[12] Cedars Sinai Med Ctr, Los Angeles, CA USA
[13] Stanford Univ, Med Ctr, Stanford, CA USA
[14] Stanford Hosp & Clin, Stanford, CA USA
[15] Univ Hlth Network, Princess Margaret, Toronto, ON, Canada
[16] Yale New Haven, Yale Sch Med, Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[17] Univ Oklahoma Hlth Sci, Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [32] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
    Wu, Fang
    Liu, Xianling
    Ma, Jin-an
    Gao, Yawen
    Hu, Chunhong
    LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124
  • [33] Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Chaib, Imane
    Santarpia, Mariacarmela
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1068 - 1070
  • [34] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Elena María Martínez-Navarro
    Joseba Rebollo
    Ramón González-Manzano
    Manuel Sureda
    Elena Evgenyeva
    Belén Valenzuela
    Francisco José Fernández
    Jerónimo Forteza
    Antonio Brugarolas
    Clinical and Translational Oncology, 2011, 13 : 812 - 818
  • [36] Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs)
    Kim, Dong-Wan
    Lee, Dae Ho
    Kang, Jin Hyoung
    Park, Keunchil
    Han, Ji-Youn
    Lee, Jong-Seok
    Jang, In-Jin
    Kim, Hyo-Yeon
    Son, Jeewoong
    Kim, Joo-Hang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
    Lemmon, Christopher
    Pennell, Nathan A.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 5042 - 5045
  • [38] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    CANCERS, 2019, 11 (07)
  • [39] A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
    Enrico, D. H.
    Lacroix, L.
    Rouleau, E.
    Scoazec, J-Y
    Loriot, Y.
    Tselikas, L.
    Jovelet, C.
    Planchard, D.
    Gazzah, A.
    Mezquita, L.
    Ngo, M.
    Michiels, S.
    Maillard, A.
    Massard, C.
    Facchinetti, F.
    Soria, J-C
    Andre, F.
    Vassal, G.
    Friboulet, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
12345